FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296435952> ?p ?o ?g. }

• W2296435952 endingPage "605" @default.
• W2296435952 startingPage "605" @default.
• W2296435952 abstract "Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study Yu Zhang,1,* Linguo Xie,1,* Tao Chen,1,* Wanqin Xie,2 Zhouliang Wu,1 Hao Xu,1 Chen Xing,1 Nan Sha,1 Zhonghua Shen,1 Yunkai Qie,1 Xiaoteng Liu,1 Hailong Hu,1 Changli Wu1 1Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 2Key Laboratory of Genetics and Birth Health of Hunan Province, The Family Planning Research Institute of Hunan Province, Changsha, People’s Republic of China *These authors contributed equally to this work Objective: The management of stage 1 and grade 3 (T1G3) bladder cancer continues to be controversial. Although the transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy is a conservative strategy for treatment of T1G3 bladder cancer, a relatively high risk of tumor recurrence and progression remains regarding the therapy. This study aimed to compare the efficacy of intravenous chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone for T1G3 bladder cancer after TURBT surgery. Methods: We retrospectively reviewed the cases of 457 patients who were newly diagnosed with T1G3 bladder urothelial carcinoma between January 2009 and March 2014. After TURBT, 281 patients received intravesical chemotherapy alone, whereas 176 patients underwent intravesical chemotherapy in combination with intravenous chemotherapy. Tumor recurrence and progression were monitored periodically by urine cytology and cystoscopy in follow-up. Recurrence-free survival and progression-free survival of the two chemotherapy strategies following TURBT were analyzed. Univariable and multivariable Cox hazards analyses were performed to predict the prognostic factors for tumor recurrence and progression. Results: The tumor recurrence rate was 36.7% for patients who received intravesical chemotherapy alone after TURBT, compared with 19.9% for patients who received intravenous chemotherapy combined with intravesical chemotherapy after TURBT (P<0.001). The progression rate was 10.6% for patients who underwent intravesical chemotherapy alone and 2.3% for patients who underwent the combined chemotherapies (P=0.003). Kaplan–Meier curves showed significant differences in recurrence-free survival and progression-free survival between the two treatment strategies, with a log-rank P-value of <0.001 and 0.003, respectively. Multivariable analyses revealed that intravenous chemotherapy was the independent prognostic factor for tumor recurrence and progression in the cohort. Conclusion: Intravenous chemotherapy combined with intravesical chemotherapy offers a better oncologic outcome than the intravesical chemotherapy alone for patients with T1G3 bladder urothelial carcinoma after TURBT, and it may be considered as a new therapy strategy for T1G3 bladder cancer. Keywords: bladder, intravenous chemotherapy, recurrence, progression" @default.
• W2296435952 created "2016-06-24" @default.
• W2296435952 creator A5000783607 @default.
• W2296435952 creator A5008731588 @default.
• W2296435952 creator A5019828141 @default.
• W2296435952 creator A5021782861 @default.
• W2296435952 creator A5024818901 @default.
• W2296435952 creator A5036210249 @default.
• W2296435952 creator A5038421414 @default.
• W2296435952 creator A5039510267 @default.
• W2296435952 creator A5046665421 @default.
• W2296435952 creator A5057337284 @default.
• W2296435952 creator A5058009437 @default.
• W2296435952 creator A5073819805 @default.
• W2296435952 creator A5075064033 @default.
• W2296435952 date "2016-01-01" @default.
• W2296435952 modified "2023-10-09" @default.
• W2296435952 title "Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study" @default.
• W2296435952 cites W128931034 @default.
• W2296435952 cites W1586540841 @default.
• W2296435952 cites W1964346483 @default.
• W2296435952 cites W1991591455 @default.
• W2296435952 cites W2001581941 @default.
• W2296435952 cites W2002045993 @default.
• W2296435952 cites W2027795491 @default.
• W2296435952 cites W2031736835 @default.
• W2296435952 cites W2032553799 @default.
• W2296435952 cites W2050256434 @default.
• W2296435952 cites W2065151446 @default.
• W2296435952 cites W2066737679 @default.
• W2296435952 cites W2084148326 @default.
• W2296435952 cites W2092624765 @default.
• W2296435952 cites W2096927220 @default.
• W2296435952 cites W2098614234 @default.
• W2296435952 cites W2101562875 @default.
• W2296435952 cites W2105407988 @default.
• W2296435952 cites W2116195839 @default.
• W2296435952 cites W2116299167 @default.
• W2296435952 cites W2135821800 @default.
• W2296435952 cites W2151781453 @default.
• W2296435952 cites W2155829623 @default.
• W2296435952 cites W2164844102 @default.
• W2296435952 cites W2335938267 @default.
• W2296435952 cites W2407504500 @default.
• W2296435952 cites W4295773318 @default.
• W2296435952 doi "https://doi.org/10.2147/ott.s99866" @default.
• W2296435952 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4734785" @default.
• W2296435952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26869805" @default.
• W2296435952 hasPublicationYear "2016" @default.
• W2296435952 type Work @default.
• W2296435952 sameAs 2296435952 @default.
• W2296435952 citedByCount "6" @default.
• W2296435952 countsByYear W22964359522017 @default.
• W2296435952 countsByYear W22964359522018 @default.
• W2296435952 countsByYear W22964359522019 @default.
• W2296435952 countsByYear W22964359522021 @default.
• W2296435952 countsByYear W22964359522023 @default.
• W2296435952 crossrefType "journal-article" @default.
• W2296435952 hasAuthorship W2296435952A5000783607 @default.
• W2296435952 hasAuthorship W2296435952A5008731588 @default.
• W2296435952 hasAuthorship W2296435952A5019828141 @default.
• W2296435952 hasAuthorship W2296435952A5021782861 @default.
• W2296435952 hasAuthorship W2296435952A5024818901 @default.
• W2296435952 hasAuthorship W2296435952A5036210249 @default.
• W2296435952 hasAuthorship W2296435952A5038421414 @default.
• W2296435952 hasAuthorship W2296435952A5039510267 @default.
• W2296435952 hasAuthorship W2296435952A5046665421 @default.
• W2296435952 hasAuthorship W2296435952A5057337284 @default.
• W2296435952 hasAuthorship W2296435952A5058009437 @default.
• W2296435952 hasAuthorship W2296435952A5073819805 @default.
• W2296435952 hasAuthorship W2296435952A5075064033 @default.
• W2296435952 hasBestOaLocation W22964359521 @default.
• W2296435952 hasConcept C121608353 @default.
• W2296435952 hasConcept C126322002 @default.
• W2296435952 hasConcept C126894567 @default.
• W2296435952 hasConcept C2776694085 @default.
• W2296435952 hasConcept C2778769751 @default.
• W2296435952 hasConcept C2780352672 @default.
• W2296435952 hasConcept C2992225637 @default.
• W2296435952 hasConcept C71924100 @default.
• W2296435952 hasConcept C77411442 @default.
• W2296435952 hasConceptScore W2296435952C121608353 @default.
• W2296435952 hasConceptScore W2296435952C126322002 @default.
• W2296435952 hasConceptScore W2296435952C126894567 @default.
• W2296435952 hasConceptScore W2296435952C2776694085 @default.
• W2296435952 hasConceptScore W2296435952C2778769751 @default.
• W2296435952 hasConceptScore W2296435952C2780352672 @default.
• W2296435952 hasConceptScore W2296435952C2992225637 @default.
• W2296435952 hasConceptScore W2296435952C71924100 @default.
• W2296435952 hasConceptScore W2296435952C77411442 @default.
• W2296435952 hasLocation W22964359521 @default.
• W2296435952 hasLocation W22964359522 @default.
• W2296435952 hasLocation W22964359523 @default.
• W2296435952 hasLocation W22964359524 @default.
• W2296435952 hasOpenAccess W2296435952 @default.
• W2296435952 hasPrimaryLocation W22964359521 @default.
• W2296435952 hasRelatedWork W1970119481 @default.
• W2296435952 hasRelatedWork W1991176685 @default.

• next